EM2411G “New Frontiers in Breast Cancer Immunotherapy” (IM GR - 112224)

Purpose and Overview

The lecture aims to educate clinicians, researchers, and trainees about the evolving landscape of breast cancer immunotherapy, highlighting novel approaches that integrate immunotherapy with non-immunotherapies. It focuses on leveraging immune mechanisms to overcome challenges posed by the immunosuppressive tumor microenvironment, particularly in aggressive subtypes such as triple-negative breast cancer. The goal is to improve understanding of key biological mechanisms, current clinical trial outcomes, and future strategies to enhance patient care.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Understand the role of chemoimmunotherapy in breast cancer: Learn how immunotherapy integrates with non-immunotherapies, such as chemotherapy and targeted therapies, to enhance anti-tumor immune responses, particularly in triple-negative breast cancer.
  • Identify emerging therapies in breast cancer immunotherapy: Explore the potential of antibody-drug conjugates, combination therapies, and novel immunomodulatory approaches in improving progression-free and overall survival across breast cancer subtypes.
  • Explore the role of dendritic cells in anti-tumor immunity: Understand the critical function of cDC1 cells in antigen presentation and how to counteract their dysfunction in breast cancers.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
11/22/2024
Course expires: 
12/31/2024
Cost:
$0.00
Rating: 
0

Photo: First Last, M.D.
Sangeetha Reddy, M.D.
Assistant Professor of Internal Medicine
Division of Hematology & Oncology

Available Credit

  • 1.00 AMA

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome